Schrödinger, Inc. (NASDAQ:SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital.

In connection with the transaction, Schrödinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform at scale to further advance these programs to clinical candidates.